NRD
FOLD

Nebula Research & Development’s Amicus Therapeutics FOLD Stock Holding History

Nebula Research & Development’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-88,957
Closed -$510K – 343
2025
Q2 		$510K Buy
88,957
+28,075
+46% +$181K 0.04% 635
2025
Q1 		$497K Buy
60,882
+3,734
+7% +$34.6K 0.05% 614
2024
Q4 		$538K Buy
57,148
+24,790
+77% +$258K 0.06% 524
2024
Q3 		$346K Buy
+32,358
New +$352K 0.04% 671
2023
Q4 		– Sell
-20,280
Closed -$247K – 722
2023
Q3 		$247K Buy
+20,280
New +$262K 0.13% 339

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Nebula Research & Development's FOLD Position: Q3 2025 in Review

Nebula Research & Development sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 88,957 shares — an estimated $510K sold.

Nebula Research & Development first reported a position in FOLD in Q3 2023 and held it in 5 quarters. The position peaked at $538K in Q4 2024. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

  • Nebula Research & Development reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 88,957 Amicus Therapeutics shares in Q3 2025, an estimated $510K.
  • Nebula Research & Development first reported a position in Amicus Therapeutics in Q3 2023 and held it in 5 quarters.
  • Nebula Research & Development's Amicus Therapeutics position peaked at $538K in Q4 2024.
  • 287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.